Announcements
- Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
- Ardelyx, Inc. Reports Employment Inducement Grants
- Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
- Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
- Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
- Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
- Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
- Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
- Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
More ▼
Key statistics
On Thursday, Ardelyx Inc (41X:DUS) closed at 7.10, -21.98% below its 52-week high of 9.10, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.07 |
---|---|
High | 7.12 |
Low | 7.07 |
Bid | -- |
Offer | -- |
Previous close | 7.15 |
Average volume | 6.18k |
---|---|
Shares outstanding | 233.98m |
Free float | 230.03m |
P/E (TTM) | -- |
Market cap | 1.83bn USD |
EPS (TTM) | -0.2883 USD |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼